Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced the initiation of a Phase 3 registration program for VX-770, an investigational Cystic Fibrosis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE